



Behçet's Disease : A Clinical Review

Hawraa Sabah Al-Musawi ¹

Israa Luay AL-jaryan ²

Zainab A. Tolaifeh ³

1. College of Science for Women, University of Babylon
ahzg.1983@gmail.com
2. Department of Animal Resources/College of Agriculture/University of Al-Qasim Green isra.alj81@gmail.com
3. College of Science for Women, University of Babylon,
zainab.tolaif@ubobabylon.edu.iq

Article Information

Submission date: 28 /6 / 2020

Acceptance date: 26 /7 / 2020

Publication date: 30 / 6 / 2020

Abstract

Behçet's disease (BD) is a rare relapsing systemic inflammatory disorder with a chronic, relapsing-remitting course of unknown etiology, current knowledge suggests that BD could follow an autoimmune process triggered by an infectious or environmental agent in genetically predisposed individuals. BD has been hallmarked predominantly by oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis, all of which represent the "stigmata" of disease. However, many other organs including the vascular, neurological, musculoskeletal, and gastrointestinal systems can be affected. BD occurs most frequently in Eurasian populations along the ancient trading route known as the "Silk Road" which extends from eastern Asia to the Mediterranean basin. The diagnosis of BD is only supported by clinical criteria and requires the exclusion of other diagnoses based on clinical presentation. There are no pathognomonic laboratorial findings of BD. This rare disease often leads to blindness and fatal systemic involvement. Main causes of death include major vessel disease and central nervous system involvement. Corticosteroids are commonly used to treat clinical manifestations of BD in combination with immunosuppressant drugs. Tumor necrosis factor (TNF)-blocking agents such as Infliximab, Etanercept, and Adalimumab have been reported to have success in patients with BD.

Keywords: Behçet's disease, auto-inflammatory, systemic vasculitis, Infliximab.

1. Introduction

Behçet disease (BD) was initially discovered by a Turkish dermatologist Hulusi Behçet in 1937 who identified three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Many physical symptoms were later described, and added to the spectrum of disease [1]. BD is an auto-inflammatory systemic vasculitis of obscure etiology. Recurrent oral ulcers, genital sores, and ocular lesions usually used to characterize BD; however many other organs including the vascular, neurological, and musculoskeletal systems as well as the gastrointestinal system can be involved. In addition, this disease is also known as Behçet syndrome and malignant aphthosis [2-4].

2. Epidemiology

Behcet disease usually has an onset in the third decade of life and is rare before puberty or after 50 years of age. It is believed that BD affects more males than females, in a proportion that varies from (1.5-5:1), and is in general more serious in male patients. However, a series of western studies (which included Brazilian studies) revealed a female predominance, but with less intense manifestations. Factors that modulate this clinical expression are still unknown [5]. A male predominance is observed in Arab populations while female predominance is evident in Japan, Korea, China, the United States, and some northern European countries. The disease has a more severe course in males and younger population. [6-10] BD has significant regional differences, with highest incidence in the Mediterranean, the Middle East, and the Far East [11]. The association of BD with the ancient trading route known as the “Silk Road” which extends from eastern Asia to the Mediterranean basin and the distribution of HLA-B5 and its HLA-B*51 subtype provides important clues to its origin. BD occurs most frequently between the latitudes 30° and 45°N in Eurasian populations. Global distribution of BD is schematized in Figure(1) [12-14]. The incidence of BD varies according to geographical location, and does not follow Mendelian rules as shown by family studies [13]. The highest prevalence is found in Turkey, with up to 420 per 100,000 persons affected. Iran, Israel, northern China, and Korea follow with the next highest prevalence [14]. The countries with the lowest prevalence are the United Kingdom, Spain, Sweden, Portugal, and the United States, ranging from 0.3 to 6.4 per 100,000 persons [15,16]. The prevalence of BD have been reported (per 100 000 inhabitants) to be 13.5 in Japan [17]; 19.5 in Saudi Arabia, 15.2 – 120/100 000 in Israel, 2.1/100 000 in Kuwait, 17 in Iraq and 7.6/100 000 in Egypt [18]; 80 in Iran [19], 14 in China [20], Within Europe, the reported prevalence (per 100 000 inhabitants) trends higher among people in the Mediterranean area; Italy 2.5, Spain 7.5 and France 2.4 excluding immigrants [21,22].




Figure (1): Global distribution of Behçet's disease [14].

3. Etiopathogenesis

BD has unknown causes; current knowledge suggests that BD could follow an autoimmune process triggered by an infectious or environmental agent in genetically predisposed individuals [23].

3.1 Genetic

Four aspects demonstrate the genetic influence on BD susceptibility: peculiar geographical distribution, familial aggregation, correlation with HLA-B51 class I antigen, and polymorphisms in genes that control immune responses. HLA-B51 allele located in the major histocompatibility complex (MHC) locus on chromosome 6p has been the most strongly associated risk factor for BD in areas along the Old Silk Route; a stronger association has been described in Turkish and Japanese patients compared to Caucasians [12]. Studies have shown that HLA-B*51 is associated with BD, with more than 60% of patients testing positive for HLA-B*51[24].

Other genes present in the MHC locus have been studied like HLAB5701, Associated with disease susceptibility and MICA (MHC class I related gene) and TNF genes; however, their participation is considered to be due to linkage disequilibrium with HLA-B51 gene [25].

Several other genes located outside the MHC region have been proposed to be involved in BD pathogenesis. Meta-analyses identified that common variants of the IL10 and encoding interleukin 23 receptor (IL23R) and encoding interleukin 12 receptor beta (IL12B2) genes were strongly associated with BD [26]. IL23 is a proinflammatory cytokine that stimulates Th17 proliferation, increases the production of inflammatory cytokines, and increases the expression of IL-23 p19 mRNA in erythema nodosum-like skin lesions in patients with active BD [27]. IL10 is known as an anti-inflammatory cytokine that inhibits the action of proinflammatory cytokines, and the up-regulation of the CD4⁺ CD25⁺ T-regulatory cells in a BD-like mouse model improved the inflammatory symptoms via IL10 [28]. Therefore, the IL10 and IL23R-IL12B2 genes may play major roles in the pathogenesis of BD. Factor V gene, also called factor V

Leiden (FVL), have been associated with thrombosis and ocular involvement in BD with controversial results [29]. Recently, the study of [30] was reported that a high percentage of patients with BD have one or several variants in AID genes. Additionally, they suggest that the association of MEFV with BD could be modulated by the HLA molecules; whereas the protective effect of the loss of function of NOD2 p.Arg702Trp polymorphism would be independent of HLA. Behcet's disease has been shown to be associated with genotoxicity as measured by cytogenetic and oxidative DNA damage assays. For example, elevation in sister chromatid exchange (SCE) in BD lymphocytes has been shown by several reports [31]. The increase in the SCE rate was evident in patients with active and inactive episodes and in patients typed positive or negative for HLA-B51 allele. The mechanism for this genotoxicity is still not clear, however, significant elevation in the oxidative damage biomarkers such as 8-hydroxy deoxyguanosine, plasma malondialdehyde and protein carbonyl was detected in BD patient's [32]. In addition, levels of ascorbic acid and antioxidant enzymes that include catalase, glutathione peroxidase and superoxide dismutase were relatively lower in BD patients than in healthy controls [33].

3.2 Infection

Infectious agents have long been proposed as triggering factors in BD development. A number of bacterial and viral microorganisms have long been postulated as possible environmental triggers of BD, specially Herpes simplex virus-1 and Streptococcus Sanguis [12,34]. The most commonly investigated microorganism in the pathogenesis of BD is Streptococcus. The relationship between streptococcal infections and BD is suggested by clinical observations such as a higher incidence of infections such as tonsillitis and dental caries, aggravation of BD and the beneficial effect of antibacterial treatments on mucocutaneous and arthritic symptoms [35]. Several Streptococcus strains have become increasingly important in infectious etiology. The development of some clinical manifestations of the disease in hypersensitivity tests against streptococcal antigens is one of the most relevant evidences [36]. In addition, antibodies against *S. sanguinis* and *S. pyogenes* were obtained more frequent in BD patients than in controls [37]. Streptococcal 65-kDa HSP from an uncommon serotype (KTH-1, strain BD113-20) of oral *S. sanguinis* has been reported to be an important trigger in the pathogenesis [14]. Neurofilament medium (Nf-M) was recently suggested as possible antigen able to trigger an immune response via molecular mimicry with bacterial HSP-65 [38]. Immunoglobulin M in BD patients has been reported able to react with some streptococcal proteins such as streptococcal α -enolase and glyceraldehyde 3-phosphate dehydrogenase [39]. Cho et al. demonstrated that the *S. sanguinis* GroEL protein is a target of the serum anti-*S. sanguinis* IgA antibody. In addition, serum IgA reactivity against recombinant *S. sanguinis* GroEL has been correlated to reactivity against recombinant human hnRNP A2/B1 suggesting how autoreactive lymphocytes may be activated by infectious triggering [40]. As BD usually starts from the oral mucosa, it has been speculated that oral microbial flora may be implicated in the pathogenesis of the disease [41]. BD patients can develop new onset oral ulceration or experience both cutaneous and systemic flare-ups following dental

procedures or surgical treatments for chronic tonsillitis [42]. Antimicrobial agents have been used successfully for treating various disease symptoms [43]. Several previous studies and our experience showed oral health impairment in BD patients compared with healthy subjects [44,45]. Oral health improvement in BD patients may positively modify their disease course. Dental treatments in BD patients could be associated with a relapse of oral aphthae in the short time but could decrease their number in longer follow-up (_6 months) [46], also leading to better oral health in the long-term follow-up. Higher levels of various Streptococci were found in the oral mucosa of BD patients. In addition, *S. sanguinis* strain resulted able to induce the secretion of inflammatory cytokines by the KTH-1 cells. It is plausible that an inflammation process induced by infectious agents in subjects with predisposing genetic background leads to the development of BD [47,48]. Several studies have investigated the association between HSV-1 and BD. Herpes Simplex Virus (HSV) type 1 can be detected in saliva, intestinal ulcers, and genital ulcers by polymerase chain reaction (PCR) in patients with BD compared with healthy controls [49,50]. In addition, a BD-like mouse model was developed by inoculation of mouse earlobes with HSV and demonstrated HSV DNA sequences in cutaneous and gastrointestinal ulcerative lesions [51]. Studd et al. in an situ DNA-RNA hybridization method, detected a higher frequency of hybridization between HSV-1 DNA and complementary RNA in mononuclear cells of BD patients compared with healthy controls. The results show the presence of at least a portion of the HSV-1 genome in mononuclear cells of BD patients [52]. Cytomegalovirus, Epstein-Barr virus, Parvovirus B19, Varicella zoster virus, Hepatitis virus have also been investigated as possible triggering factors but these studies were characterized by low-level evidences [53,54]. Recent studies have shown that the differences in salivary or gut microbiome composition may have a role in the pathogenesis. In a study of the salivary microbiome using high-throughput sequencing of the 16S rRNA V4 region, Coit et al. reported that BD patients have a significantly less diverse microbial community structure than healthy controls [55]. In another study, Consolandi et al. compared the fecal microbiota of BD patients to healthy controls. They reported both a peculiar dysbiosis of the gut microbiota and a significant decrease of butyrate production in BD patients. Authors speculated that a defect of butyrate production might lead to both reduced T regulatory cells (Tregs) responses and activation of immunopathological T-effector responses [56]. To date, the most generally accepted theory to explain the effect of infectious agents in BD is the high homology that some microorganism antigens may have with human proteins, such as that of heat shock protein (HSP 65) obtained from *Mycobacterium*, with human protein (HSP60); this cross-reaction may lead to the onset of an immune response [57]. Research on genes related to apoptosis have not shown conclusive results.

3.2 Immunity

Autoimmune reactions in BD are suggested to target primarily blood vessels, especially endothelial cells, causing the clinical presentation of vasculitis. Anti-endothelial cell antibodies (AECA) have been described in many vasculitides, including BD, thus linking their presence to the pathogenesis of the condition [58]. Lee, et al. [59]

identified α -enolase as a target antigen of IgM-type AECA in patients with BD using proteomic techniques. Several mechanisms were proposed in order to explain the action of AECAs in the pathophysiology of inflammatory diseases, including the binding of AECA to endothelial cells resulting in cell activation, which may in turn increase secretions of cytokines. AECAs might also trigger inflammatory processes by complement-dependent cytotoxicity and/or antibody-dependent cellular toxicity [14]. Activated innate immunity plays an important role in the pathogenesis of BD. Microbial triggers are sensed and processed by the innate immune system via pathogen-related and/or danger-associated molecular patterns. Overproduction of inflammatory cytokines by innate immune cells such as macrophages and dendritic cells may cause a higher production of adaptive Th1- and Th17-related cytokines. BD lesions in their early stages are predominated by neutrophils which have a predominant role in the innate immunity system, and abnormalities in their activity have been extensively reported in BD patients. The priming state of neutrophil has been reported in vivo among BD patients, and the role of T cells in the neutrophil activation has been shown in experimental studies. Elevated concentrations of proinflammatory cytokines including IL8, INF γ and TNF α may be responsible for the prime state of neutrophils [60]. IL-8 is produced by T cells and is a major chemokine known to activate leukocytes, it was assumed to represent a link between immune system activation and endothelial alteration in BD. Elevated levels of IL8 were reported in serum of BD patients, as well as in skin lesions and small vessel endothelial cells, correlating IL8 with disease activity and vascular involvement [61,62]. Neutrophils are directly involved in specific lesions of BD as histopathological analysis of BD lesions showed venous and arterial infiltrates of neutrophils. On the basis of this evidence, it has been proposed to classify BD. Surface molecules, indicating neutrophil activation status (CD10, CD14, and CD16), oxidative burst and phagocytic function of neutrophils have been explored and the presence of proactive neutrophils in BD patients was reported [63]. Tissue injury in BD can be modulated by neutrophils in several manners: neutrophils were hyperactivated, probably HLA B₅₁-associated, and usually were involved in perivascular infiltration [64]. Recently, Yavuz et al. reported that testosterone causes a significant neutrophil activation together with Th-1 type immune alterations which may explain a more aggressive disease with a higher mortality rate in male BD patients [65].

Another member of innate immunity, natural killer (NK) cells are also found in BD lesions [66]. NK cells were also identified in BD lesions where seems they have a role in driving the CD4⁺ Th1 response which is the main feature of BD lesions [67,68]. However, several studies underlined increased NK cells in the peripheral blood, in particular during the active phases of the disease [69,70]. Dysregulation of the immune system contributes to BD etiopathogenesis, with increased systemic levels of inflammatory cytokines [69]. T cell subpopulations $\gamma\delta$ T cells and cytotoxic T cells, Th1 T cells, regulatory T cells (Tregs) and Th17 cells have been shown to have a role in the pathogenesis of BD [71]. $\gamma\delta$ T lymphocytes act as the first line of host defence in mucosal immunity. An increased proportion of activated $\gamma\delta$ T cells has been shown in BD [72,73], suggesting a role for them in the pathogenesis of the disease [74]. Furthermore, accumulation of $\gamma\delta$ T cells in the sites of inflammation in BD has been

reported [75]. It's well known that CD4⁺T cells can differentiate into two types: Th1 cells subset, which secretes IFN- γ , IL-2, and TNF and promotes cell-mediated immunity, and Th2 cells, which produce IL-4, IL-5, IL-10, and IL-13 and promote antibody-mediated immunity [76]. The alteration of T cell balance, especially Th1/Th17 expansion and decreased regulation by Tregs, are supposed to have a significant role in BD pathogenesis [77,78]. In particular, increased frequencies of Th17 cells were reported in the BD cutaneous lesions [79]. Th17 and IL-17 pathways might have a part in the development and/or activity of BD [80]. IL-17 levels of BD patients with active stages of uveitis, oral and genital ulcers and articular symptoms were significantly higher compared with patients with inactive stages of the same symptoms. Hamzaoui et al. demonstrated that the percentage of circulating Th17 cells and plasma interleukin IL-17 levels were increased in active BD [81,82]. Takeuchi et al. compared the proinflammatory and Th1-, Th2-, and Th17-related cytokines frequency in a group of BD patients with recurrent uveitis and a group of remitted uveitis before and after infliximab treatment. They found higher levels of IL-1b, IL-4, IL-17A, IL-17F, IL-21, IL-22, IL-31, IFN- γ , sCD40L, and TNF- α , with a significant difference for IL-17F, in BD recurrent uveitis patients respect to the BD-remitted uveitis group, before drug infusion. In addition, only IL-10 levels were found higher in the remission group than in the other group [83]. Emmi et al. showed that cytotoxic Th1 and Th 17 cells can play a role in inducing mucosal damage during the early stages in BD patient with active intestinal involvement [84]. These results confirm that Th17 and IL-17 pathway are active and play an important role, particularly in acute attacks of the disease. Conversely, a reduction in Tregs and cytokine IL-10 were notified in the disease [85]. Due to recent progress in molecular methods and basic scientific researches, our knowledge about the disease has considerably increased. GWAS have become a very important step in understanding BD pathogenesis. New genes such as ERAP1 have been introduced which help to understand the possible pathogenic mechanism of HLA-B*51. In the future, similar studies in different populations with a higher number of patients will provide significant advances in the etiopathology of BD. Despite all these advances, clinical expression of the disease is quite heterogeneous and show regional differences. The underlying environmental and genetic factors of this situation are not fully elucidated. Being a complex disease, BD is related more than one pathogenic pathway. Although, management of the disease has evolved noticeably because of more effective and targeted therapies we still need new treatment options for severe and non-responsive cases such as biological treatments developed for the underlying etiopathological mechanism [86].

4. Diagnosis

At least two “major” signs of the disease should be present to make the diagnosis. These major signs include aphthous-like ulcerations of the oral mucosa, genital ulcerations, and uveitis [87]. Other clinical manifestations that may present through the course of the disease include audiovestibular, cardiovascular, pulmonary, gastrointestinal, central nervous system, dermatological and joint disorders. As there are no pathognomonic clinical or laboratorial findings of BD, several diagnostic criteria

have been developed during the years, all having in common the 3 major features of oral ulceration, genital ulceration and eye lesions. In 1985 during the Fourth International Conference on BD, in London, an International Study Group (ISG) for BD was created, in order to create a set of criteria for the diagnosis of BD that could be used in the future. These ISG criteria were published in 1990, considering diagnosis of BD when recurrent oral ulcers plus 2 other features are present, in the absence of other clinical explanations [88]. The pathergy test is the non-specific hyper activity of the skin following minor trauma and is a unique feature of BD [89]. It consists of the intradermal puncture of the skin with a 20-gauge or smaller needle 5mm obliquely into the patient's flexor aspect of the avascular forearm skin under sterile conditions and without injecting saline. It is considered positive when an indurated erythematous small papule or pustule forms within 48 h. Positivity of the test varies with geographical location, being positive in more than 60% of Middle Eastern patients, in 15% of Korean patients and in about 5% of Caucasian, which considerably reduces its diagnostic values in populations with low positivity [90,91]. A study demonstrated that surgical cleansing of the skin before the puncture reduced the test positivity [92]. Differential diagnosis plays a relevant role in BD. BD diagnosis is only supported by clinical criteria that require the exclusion of other diagnoses based on clinical presentation. Oral ulcerations may occur in 30–40% of the general population, and therefore cannot be considered specific of BD; in contrast, bipolar ulcerations are more specific of BD. Oral ulcerations may also be associated with hemopathy, HIV, Crohn's disease, lupus, bullous dermatosis or vitamin deficiencies. Sarcoidosis, Crohn's disease, Vogt-Koyanagi Harada [93] and Cogan syndrome [94] must be ruled out in case of ocular involvement. Venous involvement should exclude the antiphospholipid syndrome, or thrombophilia. Arterial lesions of BD may mimic Takayasu's arteritis or polycondritis. Neuro-BD is sometimes difficult to distinguish from multiple sclerosis or Susac syndrome [95]. Lastly, chronic inflammatory bowel disorders must be ruled out in case of gastrointestinal involvement [96]. When audiovestibular symptoms are present we must consider differential diagnosis with SSHL [97] and Meniere's disease [98].

5. Management

Treatment options depend on the affected organ and its severity. It is important to prioritize therapeutic options according to the disease type, severity, age, and sex of each patient. Special attention should be paid to ocular, vascular, and neurologic disease, because they are the most serious manifestations and require more aggressive treatment.

Corticosteroids

Topical corticosteroids are beneficial for oral and genital ulcerations, and can be the first-line treatment, especially for patients with mild disease, while systemic corticosteroids are the recommended treatment for patients with moderate to severe disease with ocular, vascular, gastrointestinal, or neurological involvement [99]. Although corticosteroids are widely used for patients with Behçet's disease, there has been only one placebo-controlled trial, in which 86 patients who had active disease with

genital ulcer were randomized for administration of either intramuscular methylprednisolone 40 mg or placebo every 3 weeks for 27 weeks.

Colchicine

Colchicine has been used for the treatment of Behçet's disease, particularly for mucocutaneous disease. The antiinflammatory effect of colchicine has been attributed to its disruption of microtubules in neutrophils, thereby inhibiting their migration toward chemotactic factors. In one randomized controlled trial, use of colchicine significantly reduced the rate of genital ulcers, erythema nodosum, and arthritis associated with Behçet's disease, especially among female patients [100].

Azathioprine

Azathioprine is a purine synthesis inhibitor and one of the most widely used immunosuppressive medications for Behçet's disease. In the only placebo-controlled trial, 73 patients who had Behçet's disease with or without ocular involvement, were randomly assigned for treatment with either azathioprine (2.5 mg/kg/day), or placebo. After 2 years of follow-up, the patients taking azathioprine developed less ocular disease and experienced less frequent ocular complications, oral ulcers, genital ulcers, and arthritis [101]. A retrospective analysis of 157 consecutive patients with severe uveitis (active posterior uveitis or panuveitis) treated with corticosteroids (0.5–1 mg/kg/day) and azathioprine (2.5 mg/kg/day) revealed that posterior uveitis was controlled in 92.9% of patients, of whom 51.6% were complete responders and 41.4% were partial responders [102].

Thalidomide

Thalidomide was developed in the 1950s as a sedative drug and was withdrawn in 1961 because of its teratogenic effects. However, it has been rediscovered recently as an immunomodulatory drug that suppresses tumor necrosis factor (TNF)- α -induced nuclear factor (NF)- κ B activation and adenosine triphosphate (ATP)-induced interleukin (IL)-1 β secretion [103]. By modulating the activity of NF- κ B, thalidomide can up-regulate the expression of downstream genes involved in the pathophysiology of Behçet's disease. Thalidomide has been reported to be effective in treating patients with mucocutaneous lesions [104]. Cyclophosphamide Although a systematic review of the Cochrane database concluded that there was not enough evidence to support the use of cyclophosphamide in the treatment of Behçet's disease, particularly the ocular manifestations [105], it still can be a choice for life-threatening manifestations.

Tumor necrosis factor- α inhibitors

Evidence is emerging that anti-TNF α agents are highly effective for patients with Behçet's disease. Among them, infliximab has been most frequently used, mainly for refractory ocular Behçet's disease. Although there have been no controlled trials, a considerable number of observational studies have reported that infliximab reduces the frequency of uveitis attacks, successfully treats refractory macular edema, and improves visual acuity [106]. Only one prospective study from Japan has evaluated the

efficacy of infliximab, using 3–5 mg/kg body weight every 8 weeks in patients with gastrointestinal disease. In this study, all patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 90% after 1 year [107].

Conclusion

BD is a complex syndrome characterized by significant heterogeneity of clinical manifestations with usually frequent relapses. The etiology of BD is still obscure: it is believed to be due to an autoimmune process triggered by an infectious or environmental agent in genetically predisposed individuals. As there are no laboratorial findings of BD, the diagnosis is only supported by clinical criteria. Nevertheless, a careful evaluation of endoscopic findings may help in the diagnostic interpretation, whereas the endoscopic biopsy is necessary to confirm a histopathologic diagnosis. The management of Behçet's disease has markedly improved, with better use of conventional medications and the development of newer agents such as biologics. The main goal of treatment should be aimed at avoiding and preventing the feared complications of BD that endanger the life of these patients. Despite tremendous research success. There are still many gaps that need to be fulfilled, future studies should be directed to the possibility of studying the effect of oxidative stress on the development of the disease and the appearance of symptoms in patients in addition to studying the genetic and epigenetic changes to determine the most important causes of BD especially in Iraqi population.

Conflict of Interests.

There are non-conflicts of interest.

References

- [1] M. Yıldız, O. Köker, A. Adrovic, S. Şahin, K. Barut, Ö. Kasapçopur., "Pediatric Behçet's disease - clinical aspects and current concepts" *Eur J Rheumatol.*, vol.v7, no, 1, pp.1-10. Sep. 2019.
- [2] D. G. James, "Behçet's syndrome," *New England Journal of Medicine*, vol. 301, no. 8, pp. 431–432, 1979.
- [3] R. Gallizzi, D. De Vivo, "Intestinal and neurological involvement in Behçet disease: a clinical case," *Italian Journal of Pediatrics*, vol. 43, no. 1, p. 33, 2017.
- [4] T. Sakane, M. Takeno, N. Suzuki, and G. Inaba, "Behçet's disease," *New England Journal of Medicine*, vol. 341, no. 17, pp.1284–1291, 1999.
- [5] M. Scherrer Doença de "Behçet: um enigma oriental", *An Bras Dermatol*, vol. 69, pp. 323-6, 1994.
- [6] H. Yazici, Y. Tüzün, H. Pazarli, S. Yurdakul, Y. Ozyazgan, H. Ozdoğan, S. Serdaroglu, M. Ersanli, B.Y. Ulkü, A.U. Müftüoğlu, "Influence of age of onset

and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome", *Ann. Rheum. Dis.* Dec, vol. 43, no. 6, pp. 783-9, 1984. [[PMC free article](#)] [[PubMed](#)] [[Reference list](#)]

- [7] S. Lee, D. Bang, E.S. Lee, S. Sohn, 1st Ed., Berlin, Heidelberg, New York: Behçet's disease: a guide to its clinical understanding.: Springer Verlag, 2001.
- [8] D. S. Bang, S. H. Oh, K.H. Lee, E. S. Lee, S. N. Lee, "Influence of sex on patients with Behçet's disease in Korea", *J Korean Med Sci*, vol. 18, pp. 231–5, 2003.
- [9] Y. Yazici, S. Yurdakul, H. Yazici, "Behçet's syndrome", *Curr Rheumatol Rep*, vol. 12, pp. 429–35, 2010.
- [10] J. R. Nair and R. J. Moots, "Behçet's disease", *Clin Med (Lond)*, vol. 17, pp. 71–7, 2017.
- [11] J. A. Levine and J. D. O'Duffy, "Pseudo-Behçet's syndrome-a description of twenty-three cases", In: Godeau P, Wechsler B, editors. Behçet's disease: proceedings of the sixth international conference on Behçet's disease, held in Paris, France, June 30 to July 1, 1993. Amsterdam: Elsevier Science Publishers, pp. 295–8, 1993.
- [12] D. H. Verity, J. E. Marr, S. Ohno, G. R. Wallace, M. R. Stanford, "Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives", *Tissue Antigens* 1999;54: 213–20.
- [13] M. J. Zeidan, D. Saadoun, M. Garrido, D. Klatzmann, A. Six, P. Cacoub, "Behçet's disease physiopathology: a contemporary review", *Auto Immun Highlights*, vol. 7, pp. 1–12, 2016.
- [14] S. B. Cho, S. Cho, D. Bang, "New insights in the clinical understanding of Behçet's disease ", *Yonsei Med J*, vol. 53, pp. 35–42, 2012.
- [15] F. Davatchi, F. Shahram, C. Chams-Davatchi, H. Shams, A. Nadji, M. Akhlaghi, T. Faezi, Z. Ghodsi, A. Faridar, F. Ashofteh, "Behcet's disease: From East to West", *Clin Rheumatol*, vol. 29, pp. 823–833, 2010a.
- [16] P. Leccese, Y. Yazici and I. Olivieri, "Behçet's syndrome in nonendemic regions", *Curr Opin Rheumatol*, vol. 29, pp. 12–6, 2017.
- [17] K. Nakae, F. Masaki, T. Hashimoto, G. Inaba, "Recent epidemiological features of Behçet's disease in Japan", In: *Excerpta Medica International Congress Series*. Amsterdam: Elsevier, pp. 145–145, 1993.
- [18] A. Mahr, L. Belarbi, B. Wechsler, D. Jeanneret, R. Dhote, O. Fain, F. Lhote, J. Ramanoelina, J. Coste, L. Guillevin, "Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration", *Arthritis Rheumatol*, vol. 58, pp. 3951–3959, 2008.
- [19] F. Davatchi, F. Shahram, C. Chams-Davatchi, H. Shams, A. Nadji, M. Akhlaghi, et al., "Behçet's disease in Iran: analysis of 6500 cases", *Int J Rheum Dis*, vol. 13, pp. 367–73, 2010.
- [20] M. Piga and A. Mathieu, "Genetic susceptibility to Behçet's disease: Role of genes belonging to the MHC region", *Rheumatology (Oxford)*, vol. 50, pp. 299–310, 2010.



- [21] C. Zouboulis, I. Kotter, D. Djawari, W. Kirch, P. Kohl, F. Ochsendorf, W. Keitel, R. Stadler, U. Wollina, E. Proksch, et al., "Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe", *Yonsei Med J.*, vol. 38, pp. 411–422, 1997.
- [22] C. Salvarani, N. Pipitone, M. Catanoso, L. Cimino, B. Tumiatì, P. Macchioni, G. Bajocchi, I. Olivieri, L. Boiardi, "Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A 17-year population-based study", *Arthritis Rheumatol*, Vol. 57, pp. 171–178, 2007.
- [23] S. Alipour, M. Nouri, E. Sakhinia, N. Samadi, N. Roshanravan, A. Ghavami, A. Khabbazi, "Epigenetic alterations in chronic disease focusing on Behçet disease: Review", *Biomed Pharmacother*, vol. 9, pp. 526–33, 2017.
- [24] G. Bodis, V. Toth, A. Schwarting, "Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases", *Rheumatol Ther*, 2018.
- [25] S. Marshall, "Behçet's disease", *Best Pract Res Clin Rheumatol*, vol. 18, pp. 291–311, 2004.
- [26] L. T. Morton, D. Situnayake and G. R. Wallace, "Genetics of Behçet's disease", *Curr Opin Rheumatol*, vol. 28, pp. 39–44, 2016.
- [27] W. Lew, J. Y. Chang, J. Y. Jung and D. Bang, "Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease", *Br J Dermatol*, vol. 158, pp. 505–11, 2008.
- [28] J. Shim, E.S. Lee, S. Park, D. Bang and S. Sohn, "CD4(+) CD25(+) regulatory T cells ameliorate Behçet's disease-like symptoms in a mouse model", *Cytotherapy*, vol. 13, pp. 835–47, 2011.
- [29] A. J. Chamorro, M. Marcos, I. Hernández-García, A. Calvo, J.C. Mejia, R. Cervera, et al., "Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: a systematic review and meta-analysis", *Autoimmun Rev*, vol. 12, pp. 607–16, 2013.
- [30] M. Ikbāl, M. Atasoy, I. Pirim, C. Aliagaoglu, S. Karatay, T. Erdem, "The alteration of sister chromatid exchange frequencies in Behçet's disease with and without HLA-B51", *J Eur Acad Dermatol Venereol*, vol. 20, pp. 149–152, 2006.
- [31] S. Burillo-Sanz, M. Montes-Cano, J. García-Lozano, et al., "Behçet's disease and genetic interactions between HLA-B*51 and variants in genes of autoinflammatory syndromes", *Sci Rep*, vol. 9, pp. 2777, 2019.
- [32] E.D. Sezer, K. Aksu, O. Caglayan, G. Keser, G. Karabulut, G. Ercan G, "DNA damage and its relationship with other oxidative stress parameters in Behçet's disease", *Rheumatol Int*, vol. 32, pp. 217–222, 2012.
- [33] S. Taysi, B. Demircan, N. Akdeniz, M. Atasoy, R. A. Sari, "Oxidant/antioxidant status in men with Behçet's disease", *Clin Rheumatol*, vol. 26, pp. 418–422, 2007.
- [34] T. Lehner, "The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease", *Int Rev Immunol*, vol. 14, pp. 21–32, 1997.



- [35] G. Mumcu, N. Inanc, S. Yavuz, H. Direskeneli, et al., "The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease", *Clin Exp Rheumatol*, PP. s27–31, 2007.
- [36] A. Togashi, S. Saito, F. Kaneko, K. Nakamura K, N. Oyama "Skin prick test with self saliva in patients with oral aphthoses: a diagnostic pathergy for Behçet's disease and recurrent aphthosis", *Inflammation and Allergy Drug- Targets*, vol. 10, pp. 164–70, 2011. doi: 10.2174/187152811795564109
- [37] K. Yokota, S. Hayashi, N. Fujii, K. Yoshikawa, S. Kotake, E. Isogai, et al., "Antibody response to oral streptococci in Behçet's disease", *Microbiol Immunol*, vol. 36, pp. 815–22, 1992. doi: 10.1111/j.1348-0421.1992.tb02083.x
- [38] Lule S, Colpak AI, Balci-Peynircioglu B, Gursay-Ozdemir Y, Peker S, Kalyoncu U, et al. "Behçet Disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger J", *Autoimmun.* (2017) 84:87–96. doi: 10.1016/j.jaut.2017.08.002
- [39] S.B. Cho, J.H. Lee, K.J. Ahn, S. Cho, Y. B. Park, S. K. Lee, et al., "Identification of streptococcal proteins reacting with sera from Behçet's disease and rheumatic disorders", *Clin Exp Rheumatol*, vol. 28, pp. S31–8, 2010.
- [40] S. B. Cho, Z. Zheng, K. J. Ahn, M. J. Choi, S. Cho, D. Y. Kim, et al., "Serum IgA reactivity against GroEL of *Streptococcus sanguinis* and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behçet disease", *Br J Dermatol*, vol. 168:977–83, 2013. doi: 10.1111/bjd.12128
- [41] G. Mumcu, T. Ergun, N. Inanc, I. Fresko, T. Atalay, O. Hayran, et al., "Oral health is impaired in Behçet's disease and is associated with disease severity", *Rheumatology*, vol. 43, pp. 1028–33, 2004. doi: 10.1093/rheumatology/keh236
- [42] F. Kaneko, N. Oyama and A. Nishibu, "Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms", *Yonsei Med Journal*, vol. 38, pp. 444–54, 1997. doi: 10.3349/ymj.1997.38.6.444
- [43] E. Alpsoy, "Behçet's disease: treatment of mucocutaneous lesions", *Clin Exp Rheumatol*, vol. 23, pp. 532–9, 2005.
- [44] A. Akman, H. Kacaroglu, L. Donmez, A. Bacanli and E. Alpsoy, "Relationship between periodontal findings and Behçet's disease: a controlled study", *J Clin Periodontol*, vol. 34, pp. 485–91, 2007. doi: 10.1111/j.1600-051X.2007.01085.x
- [45] H. Celenligil-Nazliel, E. Kansu and J. Ebersole, "Periodontal findings and systemic antibody responses to oral microorganisms in Behçet's disease", *J Periodontol*, vol. 70, pp. 1449–56, 1999. doi: 10.1902/jop.1999.70.12.1449
- [46] U. Karacayli, G. Mumcu, I. Simsek, S. Pay, O. Kose, H. Erdem, et al., "The close association between dental and periodontal treatments and oral ulcer course in Behçet's disease: a prospective clinical study", *J Oral Pathol Med*, vol. 38, pp. 410–5, 2009. doi: 10.1111/j.1600-0714.2009.00765.x
- [47] F. Kaneko, A. Togashi, E. Nomura and K. Nakamura, "A new diagnostic way for Behçet's disease: skin prick with self-saliva G", *enet Res Int*, vol. 581468, 2014. doi: 10.1155/2014/581468



- [48] A. Akman, N. Sallakci, H. Kacaroglu, O. Tosun, U. Yavuzer, E. Alpsoy, et al., "Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behçet's disease", *J Eur Acad Dermatol Venereol*, vol. 22, pp. 950–7, 2008. doi: 10.1111/j.1468-3083.2008.02678.x
- [49] S. Lee, D. Bang, Y. H. Cho, E. S. Lee and S. Sohn, "Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease", *Arch Dermatol Res*, vol. 288, no.4, pp. 179–183, 1996. doi:10.1007/BF02505221
- [50] S. Sohn, E.S. Lee, D. Bang and S. Lee, "Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice", *Eur J Dermatol*, vol. 8, pp. 21–3, 1998.
- [51] Sohn S, Bang D, Lee ES, Kwon HJ, Lee SI, Lee S. "Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice. *Br J Dermatol*, vol. 145, pp. 799–804, 2001.
- [52] M. Studd, D. J. McCance, T. Lehner, "Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction", *J Med Microbiol*, vol. 34, pp. 39–43, 1991. doi: 10.1099/00222615-34-1-39
- [53] M. Pineton de Chambrun, B. Wechsler, G. Geri, P. Cacoub and D. Saadoun, "New insights into the pathogenesis of Behçet's disease", *Autoimmun Rev*, vol. 11, pp. 687–98, 2012. doi: 10.1016/j.autrev.2011.11.026
- [54] Z. Saleh and T. Arayssi, "Update on the therapy of Behçet disease", *Ther Adv Chronic Dis*, vol. 5, pp. 112–134, 2014. doi: 10.1177/2040622314523062
- [55] P. Coit, G. Mumcu, F. Ture-Ozdemir, A. U. Unal, U. Alpar, N. Bostanci, et al., "Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease", *Clin Immunol*, vol. 169, pp. 28–35, 2016. doi: 10.1016/j.clim.2016.06.002
- [56] C. Consolandi, S. Turroni, G. Emmi, M. Severgnini, J. Fiori, C. Peano, et al., "Behçet's syndrome patients exhibit specific microbiome signature", *Autoimmun Rev*, vol. 14, pp. 269–276, 2015. doi: 10.1016/j.autrev.2014.11.009
- [57] T. Ergun, U. Ince, E. Eksioğlu-Demiralp, H. Direskeneli, O. Gürbüz, L. Gürses, et al., "HSP 60 expression in mucocutaneous lesions of Behçet's disease", *J Am Acad Dermatol*, vol. 45, pp. 904–909, 2001.
- [58] C. Mendoza-Pinto, M. García-Carrasco, M. Jiménez-Hernández, C. Jiménez Hernández, C. Riebeling-Navarro, A. Nava Zavala, et al., "Etiopathogenesis of Behçet's diseaseA", *utoimmun Rev*, vol. 9, pp. 241–245, 2010.
- [59] K. H. Lee, H. S. Chung, H. S. Kim, S. H. Oh, M. K. Ha, J. H. Baik, et al., "Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease", *Arthritis Rheum*, vol. 48, pp. 2025–2035, 2003.
- [60] G. Sungur, D. Hazirolan, E. Hekimoglu, R. Kasim and S. Duman, "Late-onset Behçet's disease: demographic, clinical, and ocular features", *Graefes Arch Clin Exp Ophthalmol*, vol. 248, pp. 1325–1330, 2010.
- [61] S. P. Durmazlar, G. B. Ulkar, F. Eskioglu, S. Tatlican, A. Mert and A. Akgul, "Significance of serum interleukin-8 levels in patients with Behçet's disease:



- high levels may indicate vascular involvement ", *Int J Dermatol*, vol. 48, pp. 259–264, 2009.
- [62] H. Yazici, E. Seyahi, G. Hatemi and Y. Yazici, "Behçet syndrome: a contemporary review ", *Nat Rev Rheumatol*, vol. 14, pp. 107–119, 2018.
- [63] E. Eksioğlu-Demiralp, H. Direskeneli, A. Kibaroglu, S. Yavuz , T. Ergun and T. Akoglu, "Neutrophil activation in Behçet's disease", *Clin Exp Rheumatol*, vol. 19, no. 5 Suppl. 24, pp. :S19–S24, 2001.
- [64] S. Yavuz, T. Akdeniz, V. Hancer, M. Bicakcigil, M. Can and G. Yanikkaya-Demirel, "Dual effects of testosterone in Behçet's disease: implications for a role in disease pathogenesis", *Genes Immun*, vol. 17, pp. 335–341, 2016. doi: 10.1038/gene.2016.28
- [65] R. Deniz, A. Tulunay-Virlan, F. Ture Ozdemir, A. U. Unal, G. Ozenm, Alibaz-Oner et al., "Th17-Inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behçet's disease Im", *munol Invest*, vol. 46, pp. 518–525, 2017. doi: 10.1080/08820139.2017.1306865.
- [66] M. S. Hasan, P. L. Ryan, L. A. Bergmeier and F. Fortune, "Circulating NK cells and their subsets in Behçet's disease", *Clin Exp Immunol*, vol. 188, pp. 311–322, 2017. doi: 10.1111/cei.12939
- [67] Y. Yamaguchi, H. Takahashi, T. Satoh, Y. Okazaki, N. Mizuki, K. Takahashi, et al., "Natural killer cells control a T-helper 1 response in patients with Behçet's disease ", *Arthritis Res Ther*, vol. 12, pp. R80, 2010. doi: 10.1186/ar3005
- [68] Y. Suzuki, K. Hoshi, T. Matsuda, Y. Mizushima, "Increased peripheral blood gamma delta1 T cells and natural killer cells in Behçet's disease", *J Rheumatol*, vol. 19, pp. 588–592, 1992.
- [69] M. Pineton de Chambrun, B. Wechsler, G. Geri, P. Cacoub and D. Saadoun, "New insights into the pathogenesis of Behçet's disease", *Autoimmun Rev*, vol. 11, pp. 687–698, 2012.
- [70] J. Freysdottir, L. Hussain, I. Farmer, S. H. Lau and F. Fortune, "Diversity of gammadelta T cells in patients with Behçet's disease is indicative of polyclonal activation Oral Dis, vol. 12, pp. 271–277, 2006.
- [71] P. M. van Hagen, H. Hooijkaas, M. W. Vd Beemd, G. Verjans and g. s. Baarsma, "T-gammadelta receptor restriction in peripheral lymphocytes of patients with Behçet's disease. *Adv Exp Med Biol*, vol. 528, pp.267–268, 2003.
- [72] I. Bank, M. Duvdevani and A. Livneh, "Expansion of gd T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers ", *J Lab Clin Med* 2003;141: 33–40.
- [73] K. Hamzaoui, A. Hamzaoui, F. Hentati, et al., "Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behçet's disease ", *J Rheumatol*, vol. 21, PP. 2301–2306, 1994.
- [74] M. Ben Ahmed, H. Houman, M. Miled, K. Dellagi and H. Louzir, "Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease ", *Arthritis Rheum*, vol. 50, pp. 2291–2295, 2004. doi: 10.1002/art.20334



- [75] Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et al. "Behçet's disease: New insights into pathophysiology, clinical features and treatment options", *Autoimmun Rev.* (2018) 17:567–75. doi: 10.1016/j.autrev.2017.12.006
- [76] M. Takeuchi, N. Mizuki, A. Meguro, M. J. Ombrello, Y. Kirino, C. Satorius, et al., "Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility", *Nat Genet*, vol. 49, pp. 438–443, 2017. doi: 10.1038/ng.3786
- [77] Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al., "Excessive CD4⁺ T cells co-expressing interleukin-17 and interferon-g in patients with Behçet's disease", *Clin Exp Immunol*, vol. 168, pp. 68–74, 2012. doi: 10.1111/j.1365-2249.2011.04543.x
- [78] E. Alpsoy, "Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions", *J Dermatol*, vol. 43, pp. 620–632, 2016. doi: 10.1111/1346-8138.13381
- [79] K. Hamzaoui, E. Bouali, I. Ghorbel, M. Khanfir, H. Houman and A. Hamzaoui, "Expression of Th-17 and ROR γ t mRNA in Behçet's Disease", *Med Sci Monit*, vol. 17, pp. CR227–234, 2011. doi: 10.12659/MSM.881720
- [80] M. Giza, D. Koftori, L. Chen and Bowness P. "Is Behçet's disease a 'class 1-opathy'? The role of HLA-B₅₁ in the pathogenesis of Behçet's disease", *Clin Exp Immunol*, vol. 191, pp. 11–8, 2018. doi: 10.1111/cei.13049
- [81] M. Takeuchi, Y. Karasawa, K. Harimoto, A. Tanaka, M. Shibata, T. Sato, et al., "Analysis of Th cell-related cytokine production in Behçet disease patients with uveitis before and after infliximab treatment", *Ocul Immunol Inflamm*, vol. 25, pp. 52–61, 2017. doi: 10.3109/09273948.2016.1158276
- [82] G. Emmi, E. Silvestri, C. D. Bella, A. Grassi, M. Benagiano, F. Cianchi, et al., "Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behçet patients and exhibit high levels of TNF- α in early phases of the disease", *Medicine*, vol. 95, pp. 49, 2016. doi: 10.1097/MD.00000000000005516
- [83] M. Touzot, P. Cacoub, B. Bodaghi, V. Soumelis and D. Saadoun, "IFN α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease", *Autoimmun Rev*, vol. 14, 370–375, 2015. doi: 10.1016/j.autrev.2014.12.009
- [84] S. N. Esatoglu, G. Hatemi, P. Leccese and I. Olivieri "Highlights of the 17th International Conference on Behçet's syndrome", *Clin Exp Rheumatol*, vol. 34, pp. 3–9, 2016.
- [85] T. N. Helm, C. Camisa, C. Allen and C. Lowder, "Clinical features of Behçet's disease: a report of four cases", *Oral Surg Oral Med Oral Pathol*, vol. 72, pp. 30, 1991.
- [86] International Study Group for Behçet's Disease. "Criteria for diagnosis of Behçet's disease", *Lancet*, vol. 335, pp. 1078–1080, 1990.
- [87] M. Ozdemir, S. Balevi, F. Deniz and I. Mevlitođlu, "Pathergy reaction in different body areas in Behçet's disease", *Clin Exp Dermatol*, vol. 32, pp. 85–87, 2007.



- [88] K. Omer and C. “Ertugrul, Management of Behcet’s syndrome”, *Rheumatology*, Vol. 59, no. 3, pp. iii108–iii117, May 2020.
- [89] C. Evereklioglu, “Current concepts in the etiology and treatment of Behçets disease ”, *Surv Ophthalmol*, vol. 50, pp. 297–350, 2005.
- [90] I. Kalay Yıldızhan and A. Boyvat, “Diagnostic Sensitivity of Different Applications of Pathergy Test for Behçet’s Disease”. *Arch Rheumatol*, vol. 35, no. 1, pp. 29-34, 2020.
- [91] A. Greco, M. Fusconi, A. Gallo, R. Turchetta, C. Marinelli, G. F. Macri, “Vogt-Koyanagi-Harada syndromeA”, *utoimmun Rev*, vol. 12, pp. 1033–1038, 2013.
- [92] V. D’Aguanno, M. Ralli, M. de Vincentiis and A. Greco, “Optimal management of Cogan's syndrome: a multidisciplinary approach”, *J Multidiscip Healthc*, vol. 11, pp. 1–11, 2017.
- [93] A. Greco, A. De Virgilio, A. Gallo, M. Fusconi, R. Turchetta, M. Tombolini, et al., “Susac's syndrome - pathogenesis, clinical variants and treatment approachesA”, *utoimmun Rev*, vol. 13, pp. 814–821, 2014.
- [94] F. Kaneko, A. Togashi, E. Nomura and K. Nakamura, “A new Diagnostic Way for Behçet's Disease: Skin Prick with Self Saliva ”, *Genet Res Int*, 581468, 2014.
- [95] M. Fusconi, A. Chistolini, A. de Virgilio, A. Greco, F. Massaro, R. Turchetta, et al. “Sudden sensorineural hearing loss: a vascular cause? Analysis of prothrombotic risk factors in head and neck ”, *Int J Audiol*, vol. 51, pp. 800–805, 2012.
- [96] A. Greco, A. Gallo, M. Fusconi, C. Marinelli, G. F. Macri and M. de Vincentiis, “Meniere's disease might be an autoimmune condition? ”, *Autoimmun Rev*, vol. 11, pp. 731–738, 2012.
- [97] R. Rokutanda, M. Kishimoto, M. Okada, “Update on the diagnosis and management of Behçet’s disease”, *Open Access Rheumatol.*, vol. 7, pp.1-8, 2015.
- [98] S. Yurdakul, C. Mat, Y. Tüzün, Y. Ozyazgan, V. Hamuryudan, O. Uysal, M. Senocak, H. Yazici, “A double-blind trial of colchicine in Behçet’s syndrome ”, *Arthritis Rheum*, vol. 44, no. 11, pp. 2686, 2001.
- [99] H. Yazici, H. Pazarli, C. G. Barnes, et al., “A controlled trial of azathioprine in Behçet’s syndrome”, *N Engl J Med*, vol. 322, no. 5, pp. 281–285, 1990.
- [100] D. Saadoun, B. Wechsler, C. Terrada, et al., “Azathioprine in severe uveitis of Behçet’s disease”, *Arthritis Care Res (Hoboken)*, vol. 62, no. 12, pp. 1733–1738, 2010.
- [101] K. Yasui, N. Kobayashi, T. Yamazaki and K. Agematsu, “Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated ”, *inflammationCurr Pharm Des*, vol. 11, no. 3, pp. 395–401, 2005.
- [102] M. Hello, S. Barbarot, S. Bastuji-Garin, J. Revuz and O. Chosidow, “Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis”, *Medicine (Baltimore)*, vol. 89, no. 3, pp. 176–182, 2010.
- [103] A. Saenz, M. Ausejo, BShea, G. Wells, V. Welch and P. Tugwell, “Pharmacotherapy for Behcet’s syndrome”, *Cochrane Database Syst Rev*, (2):CD001084, 2000.

- [104] S. Iwata, K. Saito, K. Yamaoka, et al. "Efficacy of combination therapy of anti-TNF- α antibody infliximab and methotrexate in refractory entero- Behçet's disease ", *Mod Rheumatol*, vol. 21, no. 2, pp. 184–191, 2011.
- [105] S. Adler, I. Baumgartner and P.M. Villiger, "Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations A retrospective analysis", *Arthritis Care Res (Hoboken)*, vol. 64, no. 4, pp. 607–611, 2012.
- [106] A. I. Giardina, A. Ferrante, F. Ciccia, M. Vadalà, E. Giardina, G. Triolo, "One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs ", *Rheumatol Int*, vol. 31, no. 1, 33–37, 2011.
- [107] A. Fasano, M. D'Agostino, G. Caldarola, C. Feliciani, C. De Simone, "Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies", *J Neuroimmunol*, vol. 239, no. 1–2, pp. 105–107, 2011.

الخلاصة

يُعد مرض بهجت من الاضطرابات الالتهابية الجهازية النادرة التي تنتشر بمسارات مزمنة متكررة غير معروفة الاسباب. تقترح الدراسات الحالية ان مرض بهجت ممكن ان يكون بسبب المناعة الذاتية للجسم ضد تجاه بعض العوامل المعدية او العوامل البيئية لدى الاشخاص المؤهلين وراثيا للاصابة. يتم تمييز المرض غالبا بوساطة التهاب الفم , القرحة التناسلية والتهاب العينية المزمن , وكلها تكون بمثابة "بصمة" للمرض . ومع ذلك، يمكن أن تتأثر العديد من الأعضاء الأخرى بما في ذلك الأجهزة الوعائية والعصبية والعضلية الهيكلية والجهاز الهضمي. يحدث مرض بهجت بشكل متكرر في السكان الأوراسيين على طول الطريق التجاري القديم المعروف باسم "طريق الحرير" الذي يمتد من شرق آسيا إلى حوض البحر الأبيض المتوسط. يتم تشخيص مرض بهجت من خلال المعايير السريرية فقط ويتطلب استبعاد التشخيصات الأخرى بناءً على الاعراض السريرية. لا توجد فحوصات مختبرية خاصة بهذا المرض. غالباً ما يؤدي هذا المرض النادر إلى العمى واعتلالات جهازية مميتة. تشمل الأسباب الرئيسية للوفاة أمراض الأوعية الدموية الرئيسية واعتلالات الجهاز العصبي المركزي. تُستخدم الكورتيكوستيرويدات بشكل شائع لعلاج المظاهر السريرية لمرض بهجت مع أدوية مثبطة للمناعة. من العلاجات التي سجلت نجاحاً في علاج مرض بهجت هو TNF مثل Infliximab و Etanercept و Adalimumab .